Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
TG Therapeutics Inc (NASDAQ: TGTX) closed the day trading at $29.73 up 1.36% from the previous closing price of $29.33. In other words, the price has increased by $1.36 from its previous closing price. On the day, 2.02 million shares were traded. TGTX stock price reached its highest trading level at $30.2495 during the session, while it also had its lowest trading level at $29.04.
Ratios:
For a better understanding of TGTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 3.86. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.91.
On October 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $50. Goldman Upgraded its Sell to Neutral on August 02, 2023, whereas the target price for the stock was revised from $16 to $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 13 ’25 when Echelard Yann sold 10,000 shares for $36.94 per share. The transaction valued at 369,400 led to the insider holds 228,816 shares of the business.
Echelard Yann bought 10,000 shares of TGTX for $369,348 on Jun 13 ’25. On Jan 03 ’25, another insider, Power Sean A, who serves as the CFO of the company, sold 11,337 shares for $30.29 each. As a result, the insider received 343,443 and left with 670,632 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 4717139968 and an Enterprise Value of 4281771520. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 79.45, and their Forward P/E ratio for the next fiscal year is 17.26. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.39 while its Price-to-Book (P/B) ratio in mrq is 17.00. Its current Enterprise Value per Revenue stands at 9.43 whereas that against EBITDA is 49.852.
Stock Price History:
The Beta on a monthly basis for TGTX is 1.88, which has changed by 0.34646738 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $21.11. The 50-Day Moving Average of the stock is -10.64%, while the 200-Day Moving Average is calculated to be -13.54%.
Shares Statistics:
Over the past 3-months, TGTX traded about 2.06M shares per day on average, while over the past 10 days, TGTX traded about 1831270 shares per day. A total of 158.03M shares are outstanding, with a floating share count of 142.90M. Insiders hold about 9.93% of the company’s shares, while institutions hold 64.21% stake in the company. Shares short for TGTX as of 1755216000 were 23538832 with a Short Ratio of 11.44, compared to 1752537600 on 24169314. Therefore, it implies a Short% of Shares Outstanding of 23538832 and a Short% of Float of 19.399999.
Earnings Estimates
As of right now, 5.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.32, with high estimates of $0.43 and low estimates of $0.21.
Analysts are recommending an EPS of between $0.96 and $0.53 for the fiscal current year, implying an average EPS of $0.76. EPS for the following year is $1.72, with 5.0 analysts recommending between $2.49 and $1.04.
Revenue Estimates
6 analysts predict $152.95M in revenue for the current quarter. It ranges from a high estimate of $157.5M to a low estimate of $150M. As of the current estimate, TG Therapeutics Inc’s year-ago sales were $83.88MFor the next quarter, 6 analysts are estimating revenue of $174.39M. There is a high estimate of $178.39M for the next quarter, whereas the lowest estimate is $170.4M.
A total of 6 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $593M, while the lowest revenue estimate was $582.8M, resulting in an average revenue estimate of $588.95M. In the same quarter a year ago, actual revenue was $329MBased on 7 analysts’ estimates, the company’s revenue will be $830.81M in the next fiscal year. The high estimate is $927M and the low estimate is $692.6M.
